Your browser is no longer supported. Please, upgrade your browser.
NeuroBo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own38.41% Shs Outstand21.62M Perf Week7.17%
Market Cap68.89M Forward P/E- EPS next Y-0.70 Insider Trans0.00% Shs Float6.41M Perf Month-1.20%
Income-28.30M PEG- EPS next Q-0.15 Inst Own39.70% Short Float3.01% Perf Quarter-8.36%
Sales- P/S- EPS this Y55.10% Inst Trans0.02% Short Ratio0.08 Perf Half Y-35.74%
Book/sh0.61 P/B5.39 EPS next Y-9.40% ROA-209.90% Target Price- Perf Year-49.85%
Cash/sh0.62 P/C5.30 EPS next 5Y- ROE-268.00% 52W Range2.70 - 7.61 Perf YTD-37.33%
Dividend- P/FCF- EPS past 5Y45.70% ROI- 52W High-56.76% Beta0.65
Dividend %- Quick Ratio14.70 Sales past 5Y- Gross Margin- 52W Low21.85% ATR0.36
Employees7 Current Ratio14.70 Sales Q/Q- Oper. Margin- RSI (14)53.94 Volatility7.90% 9.69%
OptionableYes Debt/Eq0.00 EPS Q/Q49.10% Profit Margin- Rel Volume0.23 Prev Close3.09
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.48M Price3.29
Recom2.00 SMA207.99% SMA506.61% SMA200-26.58% Volume572,680 Change6.47%
Jun-15-20Initiated H.C. Wainwright Buy $20
Jul-12-21 08:30AM  
May-17-21 05:02PM  
Apr-15-21 04:52PM  
Mar-24-21 08:00AM  
Mar-05-21 08:30AM  
Jan-21-21 04:05PM  
Jan-19-21 08:00AM  
Jan-06-21 08:30AM  
Dec-21-20 05:08AM  
Nov-13-20 04:30PM  
Sep-02-20 08:30AM  
Aug-11-20 03:00PM  
Jun-16-20 04:05PM  
May-26-20 08:30AM  
May-20-20 04:29PM  
Apr-21-20 08:30AM  
Apr-16-20 04:22PM  
Apr-14-20 09:15AM  
Mar-31-20 11:04AM  
Mar-30-20 04:30PM  
Jan-13-20 09:00AM  
Jan-10-20 05:00PM  
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.